Evidence map›Paper›PMID 28413681›Full record

ArticleMolecular and clinical oncology2017

Phase 2 study of CHOP-R-14 followed by

Reem Karmali, Melissa L Larson, Jamile M Shammo, Stephanie A Gregory, Teresa O'Brien, Parameswaran Venugopal

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Reem KarmaliDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Melissa L LarsonDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Jamile M ShammoDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Stephanie A GregoryDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Teresa O'BrienDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Parameswaran VenugopalDivision of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Rush University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this open-label, single-center, phase 2 study was to assess the efficacy and safety of dose-dense CHOP-R-14 followed by

Indexed as

CHOP-R-14consolidationdose-dense chemotherapylarge B-cell lymphomaradioimmunotherapy

Identifiers

PMID28413681
PMCPMC5374906
OpenAlexW2588047585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.